Skip to content
Evofem Biosciences, Inc.
About Us
Mission
Management
Board of Directors
Saundra Pelletier
KIM P. KAMDAR, Ph.D.
Tony O’Brien
Lisa Rarick, MD, FACOG
Colin Rutherford
Our Product
phexxi
®
Pipeline
In Development
Posters & Publications
Investors
Investor Overview
Events & Presentations
Press Releases
Stock Information
Financial Information
SEC Filings
Analyst Coverage
Corporate Governance
Committee Composition
Board of Directors
Charters + Code of Ethics
Investor Resources
Investor Contact
Investor FAQs
Contact
Investor Contact
Media Contact
General Contact
Careers
Sexual Satisfaction Results With the Vaginal pH Modulator From the Phase 3 AMPOWER Study
Post navigation
Previous:
Incorporating Direct Patient Health Outcomes into Clinical Trials for the Prevention of Urogenital Chlamydia Trachomatis Infection: Analysis of a Novel Endpoint in a Clinical Trial of EVO100 (EVO-003)
Next:
Characterization of Women Who Experienced Urinary Tract Infections in the Phase 3 Ampower Trial
Back
to
Top
